Larsen Charles 4

What Happened Charles Larsen, a director of Femasys, was credited with 34,122 derivative securities on March 19, 2026. The filing reports an award/acquisition of Series D-1 warrants (not common stock) issued as private-placement consideration under an Omnibus Amendment and Consent Agreement. The warrants have an initial exercise price of $0.58 per share (subject to adjustment); no cash value or sale proceeds were reported at grant.

Key Details

• Transaction date: March 19, 2026; Form 4 filed March 27, 2026 (filed late relative to the 2-business-day rule).
• Security: 34,122 Series D-1 warrants (derivative award), acquisition code A.
• Exercise price: $0.58 per share initially, subject to contractual adjustments (see F1).
• Exercise limits: Holder’s ability to exercise the warrants is subject to Nasdaq Capital Market limitations (see F2).
• Origin: Warrants were issued in a private placement as consideration under an Omnibus Amendment and Consent Agreement dated March 19, 2026 (see F3).
• Shares owned after transaction: not disclosed in the summary filing.

Context Warrants are derivative instruments that give the holder the right to buy common stock in the future at the exercise price; they are not the same as an immediate purchase of common shares. This entry reports issuance of warrants to a director rather than an open-market buy or sale of stock. The Form 4 was filed eight days after the transaction date, which is later than the usual 2-business-day reporting requirement and may be noted by regulators or investors tracking timeliness.